

B17

BEST AVAILABLE COPY



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 476 545 A1**

EUROPEAN PATENT APPLICATION

Application number: **91115597.6**

Int. Cl.⁵: **G01N 33/542, G01N 33/58,
G01N 33/546, //G01N33/74,
G01N33/532**

Date of filing: **13.09.91**

Priority: **14.09.90 JP 242721/90**

Date of publication of application:
25.03.92 Bulletin 92/13

Designated Contracting States:
DE FR GB IT

Applicant: **Tosoh Corporation**
4560, Kaisei-cho
Shinnanyo-shi, Yamaguchi-ken 746(JP)

Inventor: **Ikeda, Kenji**
2-7-3, Tachibanadai, Midori-ku
Yokohama-shi, Kanagawa-ken(JP)
Inventor: **Toyoda, Kazuhisa**
4-26-5, Shounandai
Fujisawa-shi, Kanagawa-ken(JP)
Inventor: **Suzuki, Hideo**
3-28-13, Chuorinkan
Yamato-shi, Kanagawa-ken(JP)

Representative: **Vossius & Partner**
Siebertstrasse 4 P.O. Box 86 07 67
W-8000 München 86(DE)

Method of and kit for immunoassay.

Using a combination of a fine particle (A) having bound thereto a fluorescent substance and an antibody reacting specifically with a target substance to be detected, and a fine particle (B) having bound thereto a quencher and an antibody reacting specifically with the target substance, through a different antigen determinant, the sandwich immunoassay is conducted and a quenching of the fluorescence is measured. Alternatively, a combination of a fine particle (C) having bound thereto one member selected from a fluorescent substance and a quencher, and a bound product (D) composed of the other member selected from the fluorescent substance and the quencher, and a known amount of the target substance is used.

EP 0 476 545 A1

This invention relates to an immunoassay, which is applied to the detection of pathogens and disease markers in clinical examinations and to the industrial immunological detection of infinitesimal amounts of target substances. It also relates to a kit for the above-mentioned immunoassay.

An immunoassay using a naturally occurring antibody or a artificially prepared antibody is characterized by a high specificity and a high sensitivity, and is utilized for detecting an infinitesimal amount of a substance. For example, immunoassays are utilized for the clinical examination of detecting disease markers specifically secreted in the case of such diseases as an infectious disease, a tumor, a myocardial infarction and a cerebral thrombosis, or for detecting an infinitesimal amount of a substance in the open air.

As described, for example, in Enzyme Immunoassay (Proteins, Nucleic acids and Enzymes, separate volume, No. 31, pages 13-26, published by Kyoritsu Shuppan K.K.), many methods for immunoassays have recently been developed. Of these methods, the latex agglutination method has been utilized for a long time for the clinical examination because the operation is simple. However, the kinds of infinitesimal substances to be tested are now increasing and also the number of items is increasing requiring such a high sensitivity which is not attainable by the latex agglutination method.

As the method popularly adopted in these days, there can be mentioned the radio-immunoassay (RIA) and the enzyme immunoassay (EIA). RIA is not favorably used in spite of a high-sensitivity performance, because the assay has a large influence on the human body. The EIA utilizing an enzyme reaction instead of using a radioisotope as the labelled substance is more frequently adopted.

From the viewpoint of simplicity of the detection system, it is desirable to develop a homogeneous process not requiring B/F separation as a substitute for the conventional heterogeneous process. Ullman et al teach that a fluorescent substance or quencher chemically bound to a sandwichable antibody can be used for an immunological reaction [Methods in Enzymology, vol. 74, 28 (1981)]. The taught process is a homogeneous process utilizing the principle that, when a sandwich is formed by an antigen-antibody reaction, by the approach of the fluorescent substance and quencher bound to the antibodies to each other, the fluorescent energy of the fluorescent substance is shifted to the exciting energy of the quencher, resulting in reduction of the fluorescence intensity of the fluorescent substance.

As described above, the conventional immunological detection method is complicated because many steps such as the B/F separation step are necessary. Moreover, since the antigen-anti-

body reaction is carried out in a heterogeneous system where the solid phase and the liquid phase are copresent and the enzyme reaction or the like is used at the final stage, a long time is required for the measurement. In the homogeneous process proposed by Ullman et al, since both of the fluorescent substance and the quencher as the labelled substances are fixed to the antibody, there is a risk of drastic reduction of the performance of the antibody and elevation of sensitivity is limited.

The present invention solves the above-mentioned problems. More specifically, in accordance with one aspect of the present invention, there is provided an immunoassay comprising the steps of:

binding a fluorescent substance and an antibody reacting specifically with a target substance to be detected, to a fine particle (A);

binding a quencher and an antibody reacting specifically with the target substance to be detected, through a different antigen determinant, to a fine particle (B);

placing said fine particle (A) and said fine particle (B) in contact with the target substance contained in a sample to form an immunoreaction product comprising the target substance sandwiched between the antibody on said fine particle (A) and the antibody on said fine particle (B); and

detecting a quenching of the fluorescence occurring due to the quencher, thereby measuring the target substance in the sample.

In accordance with another aspect of the present invention, there is provided an immunoassay comprising the steps of:

binding one member selected from a fluorescent substance and a quencher, and an antibody reacting specifically with a target substance to be detected to a fine particle (C);

binding the other member selected from the fluorescent substance and the quencher to a known amount of the target substance to form a bound product (D);

placing said antibody-bound fine particle (C) and the bound product (D) in contact with the target substance contained in a sample to competitively react the target substance in the sample and the known amount of the target substance with the antibody on said particle (C), thus forming an immunoreaction product comprising the target substance and the antibody on said particle (C); and

(4) detecting a quenching of the fluorescence occurring due to the quencher, thereby measuring the target substance in the sample.

In accordance with still another aspect of the present invention, there is provided a kit for the immunoassay comprising a fine particle (A) having bound thereto a fluorescent substance and an antibody reacting specifically with a target substance to be detected, and a fine particle (B) having bound

thereto a quencher and an antibody reacting specifically with the target substance through a different antigen determinant.

In accordance with a further aspect of the present invention, there is provided a kit for the immunoassay comprising a fine particle (C) having bound thereto one member selected from a fluorescent substance and a quencher, and an antibody reacting specifically with a target substance to be detected, and a bound product (D) composed of a known amount of the target substance and the other member selected from the fluorescent substance and the quencher.

Figure 1 is a diagram illustrating changes of the fluorescence intensity of fluorescein to the concentration of the IgE antigen in Example 1;

Fig. 2 is a diagram illustrating changes of the fluorescence intensity of fluorescein to the concentration of the FSH antigen of Example 2;

Fig. 3 is a diagram illustrating changes of the fluorescence intensity of fluorescein to the concentration of the FSH antigen in Example 3;

Fig. 4 is a diagram illustrating the relationship of the relative fluorescence intensity to the incubation time in Example 4; and,

Fig. 5 is a diagram illustrating changes of the fluorescence intensity of fluorescein to the avidin antigen concentration in Examples 5 and 6.

The immunoassay methods and kits of the present invention will be described in detail.

The immunoassay method according to the first aspect of the present invention is now described. The antibody used in the present invention is not particularly limited, as far as it is capable of reacting specifically with a target substance to be detected. Either a monoclonal antibody or a polyclonal antibody may be used. The source material is not particularly limited, and for example, there can be used mouse, rat, sheep, goat, bovine and equine. In the present invention, two kinds of antibodies are used and the reaction is carried out so that the antigen is sandwiched between these two antibodies, and therefore, the two antibodies must be combined so that binding is effected through different antigen determinants. One of the two antibodies is bound together with a fluorescent substance to a fine particle (A), and the other antibody is bound together with a quencher to a fine particle (B).

The size of the fine particles (A) and (B) is larger than the size of the molecule level but cannot be distinguished with the naked eye. For example, various colloidal particles having a diameter of about 1 nm (10 angstroms) to about 500 nm (5,000 angstroms) can be used. More specifically, there can be mentioned polymeric colloids of latexes and synthetic polymers, colloids of noble metals such

as platinum gold and silver, and colloids of inorganic oxides such as aluminum oxide and titanium oxide. A smaller particle diameter is preferable because the fluorescent substance on the fine particle (A) can be approached more closely by the quencher on the fine particle (B).

The binding of the antibody reacting specifically with the target substance to the fine particle (A) or (B) can be carried out by adopting a means customarily used for immunological reactions such as physical adsorption and chemical binding.

The fluorescent substance is bound to a fine particle (A) and the quencher is bound to a fine particle (B).

The fluorescent substance and the quencher are not particularly limited, but a preferable fluorescent substance should be selected depending upon the particular quencher. As typical combinations of the fluorescent substance and the quencher, there can be mentioned fluorescein and Texas red, pyrene butyrate and β -phycoerythrin, fluorescein and 4',5'-dimethoxy-6-carboxyfluorescein, and fluorescein and rhodamine. The fluorescent substance and the quencher can be bound either directly or indirectly to the fine particles (A) and (B), respectively. In the indirect binding, BSA, polyethylene glycol (PEG) or another substance is adsorbed on a fine particle (A) or (B) and the fluorescent substance or quencher is bound to this adsorbed substance through a covalent bond. Of these bindings, direct binding is preferable because the preparation is simple.

The thus-prepared fine particle (A) having bound thereto the fluorescent substance and the antibody reacting specifically with the target substance, and the thus-prepared fine particle (B) having bound thereto the quencher and the antibody reacting specifically with the target substance through a different antigen determinant, are placed in contact with the target substance to be detected in the sample. The order of the contact is not particularly limited, and either of the particles (A) and (B) can be contacted at first or they can be simultaneously contacted with the target substance in the sample.

By this contact, the target substance in the sample is sandwiched between the antibody on the particle (A) and the antibody on the particle (B) to form an immunoreaction product. Before the immunoreaction is caused, since the fluorescent substance and the quencher are separated from each other, they do not influence each other and they have inherent energies, respectively. However, when an immunoreaction product is produced, the fluorescent substance and the quencher are placed very closely to each other and mutually act on each other, a quenching of the fluorescence occurs due to the quencher. Since the quenching of the fluorescence has a correlation to the amount of the

immunological reaction product, the target substance contained in the sample can be determined by measuring the degree of quenching.

The immunoassay method according to the second aspect of the present invention will now be described. The same antibody, fine particles, fluorescent substance and quencher as described above with respect to the first aspect of the present invention can be used. Moreover, the binding of the antibody, fluorescent substance and quencher to the fine particles can be performed by the same procedure. However, in the second aspect of the present invention, only the fine particle (C) having bound thereto an antibody reacting specifically with a target substance and one of the fluorescent substance and the quencher are used.

Either of the fluorescent substance and the quencher can be bound onto the fine particle (C), but preferably the quencher is bound onto the particle (C). The reason is that the labelled substance can be bound onto the fine particle (C) in an amount larger than the amount bound onto the target substance, and the sensitivity is improved.

The other substance selected from the fluorescent substance and the quencher is bound to a known amount of the target substance. Either direct binding or indirect binding through a particle or a polymer can be adopted.

The fine particle (C) to which the antibody and one of the fluorescent substance and quencher are bound and the known amount of the target substance to which the other substance selected from the fluorescent substance and the quencher is bound are placed into contact with the target substance in a sample to effect a competitive reaction, whereby an immunoreaction product comprising the target substance and the antibody on the particle (C), is produced. Before the immunoreaction is caused, the fluorescent substance and the quencher on the particle (C) and the known amount of the target substance are separated from each other, and therefore, they do not influence each other and they exhibit inherent energies, respectively. However, once an immunoreaction is caused, the fluorescent substance and the quencher mutually act on each other and the energy states are changed, and a quenching of the fluorescence occurs. Since quenching of the fluorescence has a correlation to the quantity of the immunoreaction product, the target substance contained in the sample can be determined by measuring the degree of quenching.

According to the present invention, there are provided kits to be used for the above-mentioned two methods of the immunoassay.

The kit used for the first immunoassay comprises a fine particle (A) having bound thereto a fluorescent substance and an antibody reacting specifically with a target substance to be detected,

and a fine particle (B) having bound thereto a quencher and an antibody reacting specifically with the target substance through a different antigen determinant.

The kit used for the second immunoassay comprises a fine particle (C) having bound thereto one member selected from a fluorescent substance and a quencher, and an antibody reacting specifically with a target substance to be detected, and a bound product (D) composed of a known amount of the target substance and the other member selected from the fluorescent substance and the quencher.

Respective components constituting these kits are the same as those described above with respect to the immunoassay methods. Furthermore, reagents having no baneful influences on the immunoassay, such as a diluent and a stabilizer, can be incorporated in the kits.

The present invention will now be described in detail with reference to the following examples that by no means limit the scope of the invention.

Example 1

Synthesis of Fine Particle (A) Having Bound Thereto Fluorescein and Antibody and Fine Particle (B) Having Bound Thereto Rhodamine and Antibody

Two kinds of anti-IgE monoclonal antibodies recognizing different sites, respectively, were fixed to polystyrene latexes A and B having bound thereto fluorescein as the fluorescent substance and rhodamine as the quencher, respectively. More specifically, 100 g of monomeric styrene was dissolved in 500 g of water, and 10 g of SDS was added to the solution and the mixture was stirred and heated. At about 60°C, potassium persulfate was added in an amount of 0.4 g per 100 ml of water to initiate polymerization. The reaction mixture was stirred for three hours and then cooled to stop the reaction. The thus-obtained latex solution was dialyzed for 1 day with pure water. Then 200 mg of fluorescein or rhodamine was added to 10 ml of the obtained 1% solution of the polystyrene latex, and the mixture was treated for 30 minutes by an ultrasonic dispersing device. The obtained solution was dialysed for 1 day with pure water, and thus, the fluorescein- or rhodamine-bound polystyrene latex was obtained.

Then 500 µl of a buffer solution containing 0.1 M of sodium bicarbonate, 0.15 M. of sodium chloride and 0.08% by weight of sodium azide (the pH value was 8.5) was mixed with 500 µl of the fluorescein-bound polystyrene latex (100 times dilution with water), and 4 ml of pure water was further added. Then 40 µl of anti-IgE monoclonal antibody (the antibody concentration was 10

mg/ml) was added to the mixture, and the mixture was stirred. Then 5 ml of 10% polyethylene glycol having a molecular weight of 20,000 was added to the polystyrene latex, and the mixture was allowed to stand for 1 hour to effect blocking. Thus an antibody- and fluorescein-bound polystyrene latex was obtained. Reaction was carried out in the same manner as described above by using the rhodamine-bound polystyrene latex and anti-IgE monoclonal antibody recognizing a different site, whereby an antibody- and rhodamine-bound polystyrene latex was obtained.

Detection of IgE Antigen Concentration

To 50 μ l of each of the fluorescent substance- and antibody-bound latex solution and the quencher- and antibody-bound latex were added 900 μ l of standard serum containing 10 to 2,200 IU/ml of IgE antigen as a sample, and incubation was conducted for 10 minutes. Then the fluorescence intensity was measured at an exciting wavelength of 495 nm (the band path was 5 nm) and a fluorescence wavelength of 515 nm (the band path was 5 nm) by a fluorescence spectrophotometer. The thus-obtained results are shown in Fig. 1. As is seen from Fig. 1, it was confirmed that the fluorescence intensity was reduced with an increase of the amount of the antigen, and the IgE antigen concentration could be detected from the degree of reduction of the fluorescence intensity.

Example 2

Synthesis of Fine Particle (A) Having Bound Thereto Fluorescein Isothiocyanate/BSA and Antibody and Fine Particle (B) Having Bound Thereto Rhodamine Isothiocyanate/BSA and Antibody

BSA having bound thereto fluorescein isothiocyanate as the fluorescent substance and BSA having bound thereto rhodamine isothiocyanate as the quencher were fixed respectively to polyethylene latexes having fixed thereto respectively two kinds of anti-FSH monoclonal antibodies recognizing different sites. More specifically, 20 mg of fluorescein isothiocyanate (FITC) were added to 100 ml of PBS buffer containing 100 mg of BSA, and the mixture was stirred for 24 hours and dialyzed for 24 hours to obtain FITC-fixed BSA. Separately, 20 mg of rhodamine isothiocyanate (TMRITC) was added to 100 ml of PBS buffer containing 100 mg of BSA, and the mixture was stirred for 24 hours and dialyzed for 24 hours to obtain TMRITC-fixed BSA.

Separately, 500 μ l of a buffer solution containing 0.1 M of sodium bicarbonate, 0.15 M of sodium chloride and 0.08% by weight of sodium azide (the

pH value was 8.5) were mixed with 500 μ l of a 1% by weight polystyrene latex solution prepared in the same manner as in Example 1, and 4 ml of pure water was further added. Then 50 μ l of anti-FSH monoclonal antibody (the antibody concentration was 0.1 mg/ml) were added, and the mixture was stirred. Then 50 μ l of the above-mentioned FITC-fixed BSA were further added to the mixture, and the mixture was allowed to stand for 1 hour to effect blocking, whereby an FITC- and antibody-fixed latex was obtained.

A similar treatment was carried out by using anti-FSH monoclonal antibody recognizing a different site and TMRITC-fixed BSA to obtain a TMRITC- and antibody-fixed latex.

Detection of FSH Antigen Concentration

To 50 μ l of each of the thus-obtained FITC- and antibody-fixed latex solution and the TMRITC- and antibody-fixed latex solution were added 900 μ l of standard serum containing 1 to 1,000 mIU/ml of FSH antigen as a sample, and incubation was conducted for ten minutes. The fluorescence intensity was measured at an exciting wavelength of 495 nm (the band path was 5 nm) and a fluorescence wavelength of 515 nm (the band path was 5 nm) by a fluorescence spectrophotometer. The thus-obtained results are shown in Fig. 2. As is seen from Fig. 2, it was confirmed that the fluorescence intensity was reduced with an increase of the amount of the antigen, and the concentration of the FSH antigen could be detected from the degree of reduction of the fluorescence intensity.

Example 3

Synthesis of Fine Particle (A) Having Bound Thereto FITC/BSA and Antibody and Fine Particle (B) Having Bound Thereto TMRITC/BSA and Antibody

BSA having bound thereto fluorescein isothiocyanate (FITC) as the fluorescent substance and BSA having bound thereto rhodamine isothiocyanate (TMRITC) as the quencher were fixed respectively to platinum fine particles to which two kinds of anti-FSH monoclonal antibodies recognizing different sites were fixed respectively.

Namely, FITC-fixed BSA and TMRITC-fixed BSA were obtained in the same manner as described in Example 2.

Separately, 500 μ l of a buffer solution containing 0.1 M of sodium bicarbonate, 0.15 M of sodium chloride and 0.08% by weight of sodium azide (the pH value was 8.5) were mixed with 500 μ l of a solution of platinum fine particles synthesized according to the conventional method (Chemistry and Applications of Noble Metals, pages 60-71, Kodan-

sha K.K.) and 4 ml of pure water were further added. Then 50 μ l of anti-FSH monoclonal antibody (the antibody concentration was 0.1 mg/ml) were added to the mixture, and the mixture was stirred. Then 50 μ l of the above-mentioned FITC-fixed BSA were added to the mixture, and the mixture was allowed to stand for 1 hour to obtain FITC and antibody-fixed platinum particles. A similar treatment was carried out by using an anti-FSH monoclonal antibody recognizing a different site and TMRITC-fixed BSA to obtain TMRITC- and antibody-fixed platinum fine particles.

Detection of FSH Antigen Concentration

To 50 μ l of the thus-obtained FITC- and antibody-fixed platinum fine particle solution and the TMRITC- and antibody-fixed platinum fine particle solution were added 900 μ l of standard serum containing 1 to 1,000 mIU of FSH antigen as a sample, and incubation was carried out for 10 minutes. Then the fluorescence intensity was measured at an exciting wavelength of 495 nm (the band path was 5 nm) and a fluorescence wavelength of 515 nm (the band path was 5 nm) by a fluorescence spectrophotometer. The results are shown in Fig. 3. As is seen from Fig. 3, it was confirmed that the fluorescent intensity was reduced with an increase of the amount of the antigen, and the FSH antigen concentration could be detected from the degree of reduction of the fluorescence intensity.

Example 4

Synthesis of Fine Particle (A) having Bound Thereto FITC and Antibody and Fine Particle (B) Having Bound Thereto TMRITC and Antibody

In the same manner as described in Example 3, a fine platinum particle having bound thereto TMRITC and an anti-FSH monoclonal antibody and a fine platinum particle having bound thereto FITC and an anti-FSH monoclonal antibody recognizing a different antigen site were prepared.

Detection of FSH Antigen Concentration

The measurement was carried out in the same manner as described in Example 3 except that standard serum containing 387.5 mIU/ml, 775mIU/ml or 1,550 mIU/ml of FSH antigen was used, and the advance of the reaction was examined while adjusting the incubation time to 0.5, 2, 5, 10, 20, 30 or 40 minutes. The results are shown in Fig. 4. In Fig. 4, the incubation time is plotted on the abscissa and the relative fluorescence intensity, calculated based on the supposition that the flu-

orescence intensity obtained at 0.5 minute's incubation is 100, is plotted on the ordinate. As is seen from Fig. 4, even if the incubation time was short, the reaction was sufficiently advanced. Therefore, it was found that the time required for the detection can be drastically shortened.

Example 5

Synthesis of Fine Particle (C) Having Bound Thereto TMRITC/BSA and Antibody

BSA having bound thereto TMRITC as the quencher was fixed to a latex having fixed thereto an anti-avidin antibody. More specifically, 100 μ l of a 1/100 dilution of a latex of the reagent class supplied by Sekisui Chemical Co. (the particle size was 0.525 μ m and the solid content of 10% by weight) were added to 4.9 ml of 0.1 M tris-hydrochloric acid buffer having a pH value of 8.0, and 50 μ l of an anti-avidin antibody (supplied by EY Laboratory, 7.5 mg/ml) were further added to bind it to the latex particles.

To the antibody-fixed latex particles were added 50 μ l of TMRITC-fixed BSA obtained in the same manner as in Example 2, and the reaction was carried out for 2 hours. Then 500 μ l of 10% polyethylene glycol having a molecular weight of 20,000 were added to the reaction mixture and blocking was conducted for 1 hour, whereby an antibody-and TMRITC-fixed latex was prepared.

Detection of Avidin Concentration

To a microtiter plate for the fluorometry were added 50 μ l of avidin (supplied by Nakarai Tesque, 0.1 μ g/ml to 1,000 μ g/ml), 50 μ l of FITC-labelled avidin (supplied by Cappel, 0.0259 mg/ml) and 100 μ l of the antibody- and TMRITC-fixed latex. Incubation was conducted for 0.5 to 60 minutes, and the fluorescence intensity was measured at an exciting wavelength of 495 nm (the band path was 5 nm) and a fluorescence wavelength of 515 nm (the band path was 5 nm) by a microtiter fluorescence reader. The results are shown by white spots in Fig. 5. As is seen from Fig. 5, it was confirmed that the fluorescence was elevated with an increase of the amount of the antigen, and the avidin concentration could be detected with the degree of this increase.

Example 6

Synthesis of Fine Particle (C) Having Bound Thereto TMRITC/BSA and Antibody

BSA having bound thereto TMRITC as the quencher was fixed to ultrafine platinum particles

having fixed thereto an anti-avidin antibody. More specifically, 120 ml of 1% by weight citric acid (supplied by Wako Junyaku) and 60 ml of chloroplatinic acid ($\text{H}_2\text{PtCl}_6 \cdot 6\text{H}_2\text{O}$ supplied by Wako Junyaku) were added to 960 ml of water maintained at 100°C , and the mixture was refluxed and stirred for 3 hours. The mixture was cooled on an ice bath and passed through an ion exchange resin column packed with Amberlite MB-1. It was confirmed that the electric conductivity after the passage through the column was not larger than $5 \mu\text{S}/\text{cm}$.

To 1 ml of the thus-prepared solution of ultrafine platinum particles were added 4.0 ml of 0.1 M tris-hydrochloric acid buffer having a pH value of 8.0, and 50 μl of an anti-avidin antibody (7.5 mg/ml) were added to the mixture to fix the antibody to the platinum particles. Then 50 μl of TMRITC-fixed BSA prepared in the same manner as described in Example 2 were added to the antibody-fixed platinum particles, and the reaction was carried out for 2 hours. Then 500 μl of 10% by weight polyethylene glycol having a molecular weight of 20,000 were added to the reaction mixture and blocking was conducted for 1 hour. Thus, antibody- and TMRITC-fixed platinum particles were obtained.

Detection of Avidin Concentration

The measurement was carried out in the same manner as described in Example 5 except that the antibody- and TMRITC-fixed ultrafine platinum particles were used instead of the antibody- and TMRITC-fixed latex. The results are shown by black spots in Fig. 5. As is seen from Fig. 5, it was confirmed that the fluorescence intensity was elevated with an increase of the amount of the antigen, and the avidin concentration.

According to the present invention, a fluorescent substance and a quencher are bound not to an antibody but to fine particles. Therefore, the following effects are attained.

The amounts of the bound fluorescent substance and quencher can be prominently increased, and therefore, detection can be performed at a high sensitivity. The fluorescent substance and the quencher do not inhibit the antigen-antibody reaction, and therefore the antibody is not deactivated.

Since the reaction is conducted in a uniform system, that is, in a liquid phase, there is no need of conducting a complicated operation, such as B/F separation, which is conducted in the conventional method in a solid-liquid heterogeneous system. The time required for the immunoassay, which is about 1 hour in the conventional technique, can be drastically shortened. When the kit for the im-

munoassay of the present invention is used, the immunoassay can be conveniently effected in a simplified manner.

5 Claims

1. A method for an immunoassay comprising the steps of:
 - binding a fluorescent substance and an antibody reacting specifically with a target substance to be detected, to a fine particle (A);
 - binding a quencher and an antibody reacting specifically with the target substance to be detected, though a different antigen determinant, to a fine particle (B);
 - placing said fine particle (A) and said fine particle (B) in contact with the target substance contained in a sample to give an immunoreaction product comprising the target substance sandwiched between the antibody on said fine particle (A) and the antibody on said fine particle (B); and
 - detecting quenching of the fluorescence occurring due to the quencher, thereby measuring the target substance in the sample.
2. A method for an immunoassay comprising the steps of:
 - binding one member selected from the group consisting of a fluorescent substance and a quencher, and an antibody reacting specifically with a target substance to be detected, to a fine particle (C);
 - binding the other member selected from a fluorescent substance and a quencher to a known amount of the target substance to give a bound product (D);
 - placing said antibody-bound fine particle (C) and the bound product (D) in contact with the target substance contained in a sample to competitively react the target substance in the sample and the known amount of the target substance with the antibody on said particle (C), thus giving an immunoreaction product comprising the target substance and the antibody on said particle (C); and
 - detecting a quenching of the fluorescence occurring due to the quencher, thereby measuring the target substance in the sample.
3. The method according to claim 2, wherein the quencher and the antibody reacting specifically with the target substance are bound to the fine particle (C); and the fluorescent substance is bound to the known amount of the target substance to give the bound product (D).
4. The method according to any of claims 1

through 3, wherein each of the fine particles (A), (B) and (C) has a particle diameter of about 1 to 500 nm (10 to 5,000 angstroms) and is selected from the group consisting of polymeric colloids, noble metal colloids and inorganic oxide colloids.

5. The method according to any of claims 1 through 4, wherein the fluorescent substance and the quencher are bound to the respective fine particles either directly or through a substance which is adsorbed on the respective fine particles and onto which the fluorescent substance or the quencher is bound through a covalent bond. 5 10
6. The method according to any of claims 1 through 5, wherein a combination of the fluorescent substance and the quencher is selected from the group consisting of a combination of fluorescein and Texas red, a combination of pyrene butyrate and β -phycoerythrin, a combination of fluorescein and 4',5'-dimethoxy-6-carboxyfluorescein, and a combination of fluorescein and rhodamine. 15 20 25
7. A kit for an immunoassay comprising a fine particle (A) having bound thereto a fluorescent substance and an antibody reacting specifically with a target substance to be detected, and a fine particle (B) having bound thereto a quencher and an antibody reacting specifically with the target substance through a different antigen determinant. 30 35
8. A kit for an immunoassay comprising a fine particle (C) having bound thereto one member selected from the group consisting of a fluorescent substance and a quencher, and an antibody reacting specifically with a target substance to be detected, and a bound product (D) composed of a known amount of the target substance and the other member selected from the group consisting of the fluorescent substance and the quencher. 40 45
9. The kit for an immunoassay according to claim 8, wherein the fine particle (C) has bound thereto the quencher and the antibody reacting specifically with the target substance, and the bound product (D) is composed of the known amount of the target substance and the fluorescent substance. 50
10. The kit for an immunoassay according to any of claims 7 through 9, wherein each of the fine particles (A), (B) and (C) has a particle diameter of about 1 to 500 nm (10 to 5,000 ang-

stroms) and is selected from the group consisting of polymeric colloids, noble metal colloids and inorganic oxide colloids.

11. The kit for an immunoassay according to any of claims 7 through 10, wherein the fluorescent substance and the quencher are bound to the respective fine particles either directly or through a substance which is adsorbed on the respective fine particles and onto which the fluorescent substance or the quencher is bound through a covalent bond. 5 10
12. The kit for an immunoassay according to any of claims 7 through 11, wherein a combination of the fluorescent substance and the quencher is selected from the group consisting of a combination of fluorescein and Texas red, a combination of pyrene butyrate and β -phycoerythrin, a combination of fluorescein and 4',5'-dimethoxy-6-carboxyfluorescein, and a combination of fluorescein and rhodamine. 15 20 25

FIG. 1




FIG. 2




FIG. 3




FIG. 4





FIG. 5





European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 11 5597

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X Y	EP-A-0 063 852 (SYVA COMPANY) * the whole document * ---	1-12 4, 10	G01N33/542 G01N33/58 G01N33/546 //G01N33/74 //G01N33/532
X	US-A-4 654 300 (R. F. ZUK ET AL.) * the whole document * ---	1, 2, 4, 5, 7, 8, 10, 11	
X	US-A-4 261 968 (E. F. ULLMAN ET AL.) * Columns 1-8. * ---	2, 5, 6, 8, 11, 12	
X, D	METHODS IN ENZYMOLOGY vol. 74, no. C, 1981, pages 29 - 61; E. F. ULLMAN ET AL: 'Fluorescence Excitation Transfer Immunoassay (FETI).' * the whole document * ---	2, 6, 8, 12	
Y	EP-A-0 370 561 (H. B. T. HOLLAND BIOTECHNOLOGY B. V.) * page 2, line 29 - page 4, line 9 * ---	4, 10	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
A	EP-A-0 354 847 (CYBERFLUOR INC.) * page 2 * ---	5, 6, 12	G01N
A	WO-A-8 707 385 (ETHIGEN CORP.) * page 5 - page 9 * ---	1, 2, 6	
A	EP-A-0 092 344 (AMERSHAM INTERNATIONAL) * page 1 - page 6 * -----	1-4, 6	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 03 DECEMBER 1991	Examiner HITCHEN C. E.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			

EPO FORM 1503 03/82 (P0001)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☒ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)